Provided by Tiger Trade Technology Pte. Ltd.

Aprea Therapeutics, Inc.

0.8052
+0.164925.75%
Pre-market: 0.84000.0348+4.32%04:54 EDT
Volume:2.80M
Turnover:2.17M
Market Cap:10.14M
PE:-0.86
High:0.8500
Open:0.7042
Low:0.6801
Close:0.6403
52wk High:1.69
52wk Low:0.5480
Shares:12.59M
Float Shares:7.91M
Volume Ratio:84.25
T/O Rate:35.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9400
EPS(LYR):-1.9269
ROE:-46.15%
ROA:-27.73%
PB:0.26
PE(LYR):-0.42

Loading ...

Company Profile

Company Name:
Aprea Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
3805 Old Easton Road,Doylestown,Pennsylvania,United States
Zip Code:
18902
Fax:
- -
Introduction:
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Directors

Name
Position
Oren Gilad
Chief Executive officer and Director and President
Bernd R. Seizinger
Director
Gabriela Gruia
Director
Jean Pierre Bizzari
Director
John B. Henneman, III
Director
Marc Duey
Director
Michael Grissinger
Director
Richard Peters
Director
Rifat Pamukcu
Director

Shareholders

Name
Position
John P. Hamill
Chief Financial Officer and Secretary and Senior Vice President
Oren Gilad
Chief Executive officer and Director and President